Navigation Links
Mayo Clinic researchers find new treatment for constipation
Date:5/10/2011

ROCHESTER, Minn. - Constipation is definitely not a glamorous topic. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat. While not often life threatening, the pain, bloating, discomfort, and straining associated with constipation lead sufferers to focus on one thing - relief. Mayo Clinic researchers recently had success in the clinical trial of a new medication shown to provide relief from constipation in a way that capitalizes on the body's natural processes.

The drug, called A3309, targets bile acid recycling in the body. Bile acids, created in the liver and released into the digestive system, aid in breaking down fats and absorbing them into the body. Bile acids also are natural laxatives that promote bowel movements by softening stool and speeding up how fast stool moves through the colon. During digestion, most bile acids are absorbed back into the blood in the lower small intestines for recycling, letting very little bile acids to leak into the colon to help facilitate bowel movements. A3309 works by inhibiting bile acid absorption in the small intestines, allowing more bile acids to enter the colon to stimulate bowel movements.

"The new medication is a novel approach which allows the delivery to the colon of normal substances produced by the patient's own liver to induce a laxative effect," says Michael Camilleri, M.D., a gastroenterologist and Atherton and Winifred W. Bean Professor at Mayo Clinic and the study's lead author.

In a Phase II, randomized, double-blind, placebo-controlled study, the Mayo Clinic research team tested the effectiveness of A3309 for two weeks in patients with constipation. The study yielded promising results. The drug sped up the movement of stool through the colon. Patients with constipation who took A3309, compared to those who received placebo, reported significantly less straining and softer stool during bowel movements, says researcher Banny Wong, M.D.

The main side effect of A3309 was abdominal discomfort and pain. Dr. Wong says this occurred mainly before a bowel movement, after which the pain and discomfort usually went away.

According to Dr. Wong, the next step in the drug's development will be Phase III studies that will involve more people and a longer treatment duration.

Dr. Wong is sharing the study's findings at the 2011 Digestive Disease Week international conference May 7-10 at McCormick Place in Chicago.


'/>"/>

Contact: Brian Kilen
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic studies how much practice makes perfect when performing colonoscopies
2. Cedars-Sinais mobile medical clinics receive $500,000 grant from California Community Foundation
3. TGen licenses first drug for patient use in clinical care
4. Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes
5. ENERCA clinical recommendations for sickle cell disease management and prevention in children
6. Mayo Clinic finds new genetic cause of neurodegeneration
7. Mayo Clinic finds robotic surgery effective for removing hard-to-reach throat cancer
8. UofL nursing faculty honored for race track clinic success
9. Tierney named 2011 Clinical and Translational Research Distinguished Investigator
10. New Pill for MS Shows Promise in Clinical Trial
11. Mayo Clinic finds tool to predict disability timeline for progressive MS patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: